Is It Possible to Defeat Arthritis?
What is Arthritis?
Arthritis manifests through the structural damage of the joints under the impact of their chronic inflammation (Senthelal, Li, Goyal, Bansal, & Thomas, 2020). Pain is the predominant symptom of arthritis. Arthritis is not synonymous with arthralgia in scenarios where pain does not necessarily originate under the impact of joint(s) inflammation. The articular pathology predominantly leads to the development of arthritic pain in the affected patients. The pain patterns potentially deteriorate the health-related quality of life of arthritic patients.
What is the Mechanism of Arthritic Pain Development?
Arthritis-related pain develops through the induction of the following
mechanisms (Kidd, Langford, & Wodehouse, 2007).
1.
The articular pain
receptor sensitization occurs under the influence of mediators belonging to
tissues, bone, and synovium.
2.
The pain receptor
stimulation occurs abruptly under the impact of mechanical stimuli, including
standing and walking activities that eventually lead to the localization of
arthritic pain.
3.
The topical and
systemic therapies attempt to control the production of inflammatory mediators
in arthritis patients.
4.
The pain patterns
of the arthritis patients emanate under the impact of non-noxious stimuli and
environmental (toxic) factors that potentially interact with the genes of the
arthritis patients, thereby leading to the development of peripheral and
central sensitizations.
5.
The limited
threshold of the peripheral sensitizations triggers localized pain and
tenderness in arthritis patients.
6.
The central
sensitizations induce diffusely modified pain perceptions while triggering
tenderness and regional or referred pain.
7.
The patients
affected with rheumatoid arthritis and osteoarthritis experience neural
sensitizations that potentially trigger their localized pain patterns.
8.
Rheumatoid
arthritis triggers spinal neurons following topical capsaicin application that
expands the anatomical regions of punctate hyperalgesia.
9.
The spinal neuronal
excitations in rheumatoid arthritis patients elevate the level of their joint
tenderness and pain perceptions.
10.
The somatic
structures along with their inputs and descending inhibitory controls trigger
the spinal nociceptive processing in the arthritis patients.
11.
The genetic
attributes and pain episodes of the arthritis patients deteriorate their daily
activities as well as health-related quality of life.
12.
The arthritis
patients encounter the impact of numerous inflammatory and pain mediators that
warrant the administration of multiple therapeutic interventions.
13.
The therapies
including NSAIDs (non-steroidal anti-inflammatory drugs), TENS (transcutaneous
electrical nerve stimulation), and acupuncture interventions assist in
mitigating the inflammatory/pain mediators in the arthritis patients.
14.
The arthritis
patients’ social and psychological factors play a pivotal role while
exaggerating or reducing the intensity and/or severity of their pain
patterns.
15.
The environmental
factors impact cortical or supraspinal levels in a manner to alter nociceptive processing
in arthritis patients that eventually disrupts their behavior and pain
perceptions to many folds.
16.
The arthritis
patients affected with central sensitization rarely acquire relief from the
administration of spinally/peripherally active therapies.
17.
The arthritis
patients’ cortical tissues and their opioid/prostanoid receptors prove to be
the therapeutic targets for their pain management.
18.
The
non-pharmacological interventions including cognitive behavior therapy and
education assist the arthritis patients to increase their overall pain
perception control levels.
What Causes Arthritis?
Arthritis and its types develop under the influence of the following
factors (IQWiG, 2020) (Poudel & Lappin, 2020) (Akhondi & Gupta,
2020).
1.
Autoimmune diseases
potentially elevate the risk of arthritis.
2.
The disruption of
healthy cells by the body’s defense mechanism due to autoimmune complications
triggers inflammatory responses that lead to the development of arthritis and
its clinical complications.
3.
Genetic
predisposition also determines the risk of arthritis complications.
4.
Bacterial and viral
infections elevate the predisposition of individuals towards
arthritis.
5.
Smoking for
extended-term triggers the onset of rheumatoid arthritis in high-risk
people.
6.
The most commonly
impacted joints in rheumatoid arthritis include toe joints, ankle joints, knee
joints, hip joints, finger joints, wrist joints, elbow joints, and shoulder
joints.
7.
Metabolic
complications, including hypercalcemia, pseudogout, serum uric acid elevation,
and gout increase the risk of arthritis.
8.
Traumatic
conditions or injuries increase the risk of osteoarthritis, particularly among
elderly people.
9.
Inflammatory
arthritis progresses through the development of reactive arthritis,
immune-related arthritis, crystal-induced arthritis, and infectious
arthritis.
10.
Some of the
arthritis causing pathogens include Rubella, Enterovirus, Parvovirus,
Coccidiomycosis, Sporotrichosis, Borrelia burgdorferi, Brucellosis,
Mycobacterial species, Anaerobic bacteria, Neisseria gonorrheae, Streptococcal
pneumoniae, and Staphylococcus aureus. These organisms variably impact
populations based on their geographic locations and age patterns.
11.
Monomicrobial
infection leads to the development of septic arthritis.
12.
The joint space
(penetrating) trauma increases the risk of polymicrobial infections and
associated arthritis.
13.
Intravenous drug
abuse and/or traumatic conditions lead to the development of gram-negative
bacterial infections and septic arthritis.
14.
Pseudogout and gout
due to monosodium urate crystals’ deposition trigger the development of
crystal-induced arthritis.
15.
Gout develops under
the impact of hyperuricemia.
16.
Overconsumption of
protein-rich food items, uric acid elevation, and renal uric acid secretion
increases the risk of arthritis and its comorbidities.
17.
Gout also develops
under the impact of chronic kidney disease, loop diuretics/thiazide
administration, alcoholism, obesity, and the male gender.
18.
The inflammatory
response due to calcium pyrophosphate crystal accumulation increases the risk
of pseudo-gout.
19.
The accumulation of
calcium pyrophosphate crystals occurs due to several conditions including
hemochromatosis, familial chondrocalcinosis, and joint trauma.
20.
The conditions
including systemic sclerosis, Sjogren syndrome, polymyositis, dermatomyositis,
SLE (systemic lupus erythematosus), and rheumatoid arthritis increase the risk
of immune-related arthritis.
21.
The joint
infections that cause reactive arthritis assimilate inside the body in a manner
that makes the recovery of respective pathogens almost impossible from the
affected joints.
22.
Some of the
urogenital and gastrointestinal pathogens causing arthritis include
Campylobacter, Shigella, Salmonella, Yersinia, and Chlamydia
trachomatis.
23.
Familial
Mediterranean fever increases the risk of infective arthritis.
24.
The non-articular
causative factors of arthritis include somatoform pain disorder, depression,
and hypothyroidism.
What are the Various Types of Arthritis and their Risk Factors?
Evidence-based clinical literature reveals almost 100 types of arthritic
conditions that impacted the health and wellness of more than ninety-one
million individuals in 2015 (Akhondi & Gupta, 2020). Some of the arthritic
conditions along with their predisposing attributes or risk factors are
documented below (Medical News Today, 2020).
1.
Arthritis emanating
from psoriasis and/or colitis
2.
Ankylosing
arthritis
3.
Reactive
arthritis
4.
Rheumatoid
arthritis
5.
Mechanical/degenerative
arthritis
6.
Infectious
arthritis
7.
Osteoarthritis
8.
Metabolic
arthritis
9.
Septic
arthritis
10.
Childhood or
juvenile idiopathic arthritis
11.
Fibromyalgia
12.
Psoriatic
arthritis
13.
Gout
14.
Sjogren’s
Syndrome
15.
Scleroderma
16.
Systemic Lupus
Erythematosus
What is the Pathophysiology of Arthritis?
Arthritis and its types develop under the impact of the following
pathological processes (Poudel & Lappin, 2020).
1.
Inflammatory
arthritis develops following the accumulation of inflammatory cells across the
synovial membrane.
2.
The synovial
accumulation of granulocytes, lymphocytes, and macrophages worsens the
arthritis symptoms.
3.
The synovial
fibroblast hyperplasia elevates the level of joint/cartilage deterioration in
arthritis patients.
4.
Synovial infection
is a predominant finding in inflammatory arthritis.
5.
The immune
complexes of the viruses like enteroviruses, Parvoviruses, and Rubella infect
skin and joints, thereby leading to the development of skin rash, arthralgia,
and arthritis.
6.
The interaction of
environmental and genetic factors leads to the development of rheumatoid
arthritis.
7.
MHC (major histocompatibility
complex) genes and HLA (human leukocyte antigen) predominantly enhance the risk
of rheumatoid arthritis.
8.
Smoking increases
the expression of peptide arginine deiminase inside alveolar macrophages that
supports the formation of citrulline from arginine.
9.
The interaction of
the adaptive immune system with neoantigens triggers the inflammatory processes
of rheumatoid arthritis.
10.
The increased
activity of anti-citrullinated protein antibodies and protein citrullination
elevates the immune reactivity pattern in rheumatoid arthritis patients.
11.
The inflammatory
mechanisms in gout reciprocate with the joint-related accumulation of
monosodium crystals.
12.
The inflammatory
cascade in gout is triggered after neutrophil activation that induces the
release of lysosomal enzymes and superoxide in the joints of the affected
patients. These processes begin under the impact of MSU crystal-immunoglobulin
binding.
How Could You Diagnose Arthritis?
The assessment of the following conditions is paramount to the clinical
diagnosis of arthritis (Poudel & Lappin, 2020).
1.
Inflammatory
arthritis progresses with anemia of chronic disease, thrombocytosis, and
CRP/ESR elevation. The assessment of these clinical parameters is, therefore,
highly necessary for the assessment of inflammatory arthritis.
2.
Joint stiffness is
another significant finding that substantiates arthritis development. However,
the activity-induced reduction in joint stiffness is a predominant finding of
inflammatory arthritis.
3.
Osteoarthritis
manifests with the development of stiffness that lasts for less than sixty
minutes and gains intensity after physical activity.
4.
The joint pain
assessment should be accompanied by the affirmation of non-articular or
articular symptoms.
5.
Acute arthritis
based on pseudo-gout, gout, or infection is accompanied by the pain of fewer
than 42 days/six-weeks duration. The extension of symptom duration beyond
6-weeks tenure supports the clinical finding of chronic arthritis.
6.
The arthritis
condition that impacts fewer than 3 joints is classified as
oligo-arthritis.
7.
The arthritis
condition that impacts more the 2 joints is categorized as polyarthritis.
8.
Arthrocentesis is
the preferred diagnostic approach to rule out crystal-induced or infectious
arthritis.
9.
Rheumatoid
arthritis is associated with erosions that require radiological
examination.
10.
Some of the
significant lab investigations for arthritis include crystal search, culture,
gram stain, differential count, and hemogram.
11.
The clinically
significant septic arthritis associates with a single swollen painful joint and
fever. Therefore, the assessment of body temperature and joints is highly
needed to rule out septic arthritis.
12.
The synovial fluid
aspiration for joint infection assessment should precede the administration of
antibiotics.
13.
The synovial fluid
requires laboratory assessment based on crystal evaluation, differential
leucocytes count assessment, culture, and gram staining.
14.
An increase in
polymorphonuclear lymphocytes above 20,000 mm-cube reveals the development of
septic arthritis.
15.
The elevation of
polymorphonuclear lymphocytes above 2000-20,000 mm-cube indicates crystal
deposition and autoimmune process activation under the impact of inflammatory
arthritis.
16.
Pseudo-gout is
marked by the deposition of rhomboid-shaped crystals.
17.
Gouty arthritis
progresses with the deposition of needle-shaped yellow crystals.
18.
Rheumatoid
arthritis affirmation is based on clinical assessments including CRP/ESR
elevation, anti-citrullinated protein antibody, and rheumatoid factor
elevation.
19.
Spondyloarthropathy
is revealed by one or more of the several complications including inflammatory
eye disease, inflammatory bowel disease history, and inflammatory back
manifestations.
20.
The differential
diagnoses include psoriatic arthritis, Lyme arthritis, juvenile idiopathic
arthritis, osteoarthritis, and ankylosing spondylitis.
How Could You Treat Arthritis?
EULAR (European League Against Rheumatism) has recommended the following
treatment algorithm for rheumatoid arthritis management (Kohler, Gunther,
Kaudewitz, & Lorenz, 2019) (Wilsdon & Hill, 2017).
1.
The treatment
phase-I is based on the administration of conventional synthetic DMARDs
(Disease-Modifying Anti-Rheumatic Drugs) with methotrexate followed by
short-term administration of glucocorticoids (in reduced dosage).
2.
The patients with
methotrexate contraindications should receive sulfasalazine/leflunomide
combination.
3.
6-months of
consistent phase-I treatment focuses on improving the RA (rheumatoid arthritis)
symptomatology.
4.
The failure of
phase-I therapy necessitates the administration of phase-II intervention.
5.
The phase-II
therapy begins with the administration of Il-6 inhibitor, or abatacept/TNF
inhibitor or a combination of sulfasalazine, leflunomide, and
methotrexate.
6.
The phase-II
intervention should acquire its therapeutic goals within a tenure of
6-months.
7.
The phase-III
treatment follows the failure of the phase-II intervention.
8.
The phase-III
treatment warrants the administration of biologic DMARD including rituximab, or
Il-6 inhibitor, or abatacept, or TNF inhibitor.
9.
The phase-III
therapy also requires a duration of 6-months for achieving the therapeutic
targets.
10.
The targeted
arthritis management therapy requires the administration of tofacitinib and/or
Janus Kinase Inhibitors.
Osteoarthritis management reciprocates with the following conservative
measures (Sen & Hurley, 2020) (Wu, Goh, Wang, & Ma, 2018).
1.
Physical
therapy
2.
Analgesia
3.
Arthroplasty
4.
Reduction of joint
overloading/physical activities for pain management
5.
Exercise to enhance
endurance
6.
Weight loss
7.
Joint unloading
through crutch, cane, splint, and brace
8.
Administration of
oral/topical NSAIDs and acetaminophen
9.
Glucocorticoid/intra-articular
injections for pain management
10.
Duloxetine therapy
Is There a Way to Prevent Arthritis?
The reduction in modifiable risk factors is the only viable strategy to
reduce the risk of osteoarthritis. Some of these approaches are mentioned below
(Deane, 2013).
1.
Antimicrobial
therapy to reduce the risk of autoimmunity development after contracting an
infectious disease
2.
Smoking
cessation
3.
Immunomodulatory
therapy
4.
Enhancement of
socioeconomic status
5.
Protection from
occupational dust
6.
Nutritional/dietary
management
7.
Reduction in
alcoholism
8.
Statin
therapy
9.
Stress
management
10.
Regular
exercise
Is There Any Herbal Remedy for Treating Arthritis?
The below-mentioned polyherbal formulations claim to treat arthritis and
its signs/symptoms (Choudhary et al. 2015).
1.
Majoon
Suranjan
2.
Sudard
3.
Tongbiling (TBL-II)
4.
Rumalya Forte
Tablet
5.
Rumalya
Liniment
6.
Artha Cure
Oil
7.
Artha Cure
Capsule
8.
Rheumarthro Gold
Capsule
9.
Ortho Joint
Oil
10.
Rheuma Off
Gold
11.
HLXL (Huo Luo Xiao
Ling Dan)
12.
GHJTY
(Ganghwaljetongyeum)
The researchers also claim the therapeutic advantages of the following
plant species in arthritis management(Choudhary et al. 2015).
1.
Xanthium strumarium
Linn. (XS)(Family-Compositae)
2.
Vitex negundo Linn.
(VN)(Family-Verbenaceae)
3.
Trigonella
foenum-graecum Linn. (TF)(Family-Papilionaceae)
4.
Terminalia chebula
Retz. (TC)(Family-Combretaceae)
5.
Sida rhombifolia
Linn. (SR)(Family-Malvaceae)
6.
Saussurea lappa
Clarke. (SL)(Family-Compositae)
7.
Ruta graveolens
Linn. (RG)(Family-Rutaceae)
8.
Punica granatum
Linn. (PG)(Family-Lythraceae)
9.
Piper longum Linn.
(PL)(Family-Piperaceae)
10.
Phyllanthus amarus
Schum and Thomm. (PA)(Family-Euphorbiaceae)
11.
Lantana camara
Linn. (LC)(Family-Verbenaceae)
12.
GY
(Family-Fabaceae)
13.
Curcuma longa Linn.
(CL)(Family-Scitaminaceae)
14.
Coriander sativum
Linn. (CS)(Family-Umbelliferae)
15.
Cinnammomum
zeylicanium Blume. (CZ)(Family-Lauraceae)
16.
Cannabis sativum
Linn. (CT)(Family-Urticaceae)
17.
Caesalpinia sappan
Linn. (CP)(Family-Leguminosae)
18.
Boswellia serrate
Roxb. (BS)(Family-Burseraceae)
19.
Boerhaavia diffusa
Linn. (BD)(Family-Nyctagineae)
20.
Aristolochia bracteolate
Lam. (AB)(Family-Aristolochiaceae)
21.
Alstonia scholaris
Linn. (AS)(Family-Apocynaceae)
References
Akhondi, H., &
Gupta, N. (2020). Polyarticular Arthritis. In StatPearls. Treasure
Island (Flordia): StatPearls Publishing. Retrieved from
https://www.ncbi.nlm.nih.gov/books/NBK537170/
Choudhary, M., Kumar,
V., Malhotra , H., & Singh , S. (2015). Medicinal plants with potential
anti-arthritic activity. Journal of Intercultural Ethnopharmacology, 4(2),
147-179. doi:10.5455/jice.20150313021918
Deane , K. (2013). Can
Rheumatoid Arthritis Be Prevented? Best Practice & Research Clinical
Rheumatology, 27(4), 467-485. doi:10.1016/j.berh.2013.09.002
IQWiG. (2020).
Rheumatoid arthritis: Overview. In InformedHealth.org. Retrieved from
https://www.ncbi.nlm.nih.gov/books/NBK384455/
Kidd, B. L., Langford ,
R. M., & Wodehouse, T. (2007). Arthritis and pain. Current approaches in
the treatment of arthritic pain. Arthritis Research and Therapy, 9(3).
doi:10.1186/ar2147
Kohler, B. M., Gunther,
J., Kaudewitz, D., & Lorenz, H. M. (2019). Current Therapeutic Options in
the Treatment of Rheumatoid Arthritis. Journal of Clinical Medicine, 8(7).
doi:10.3390/jcm8070938
Medical_News_Today.
(2020). What are the causes and types of arthritis? Retrieved from
https://www.medicalnewstoday.com/articles/7621
Poudel, P., &
Lappin, S. L. (2020). Inflammatory Arthritis. In StatPearls. Treasure
Island (Florida): StatPearls Publishing. Retrieved from
https://www.ncbi.nlm.nih.gov/books/NBK507704/#_article-23507_s2_
Sen, R., & Hurley ,
J. A. (2020). Osteoarthritis. In StatPearls. Treasure Island
(Florida): StatPearls Publishing. Retrieved from
https://www.ncbi.nlm.nih.gov/books/NBK482326/
Senthelal, S., Li, J.,
Goyal, A., Bansal , P., & Thomas , M. A. (2020). StatPearls. In Arthritis.
Treasure Island (Florida): StatPearls Publishing. Retrieved from
https://www.ncbi.nlm.nih.gov/books/NBK518992/
Wilsdon, T. D., &
Hill, C. L. (2017). Managing the drug treatment of rheumatoid arthritis. Australian
Prescriber, 40(2), 51-58. doi:10.18773/austprescr.2017.012
Wu, Y., Goh, E. L.,
Wang, D., & Ma, S. (2018). Novel treatments for osteoarthritis: An
update. Open Access Rheumatology, 10, 135-140.
doi:10.2147/OARRR.S176666